*ST双成：公司主要收入来源为药品销售收入，主要品种为注射用胸腺法新、注射用紫杉醇等

Group 1 - The company responded to an investor inquiry regarding the export volume of paclitaxel in the fourth quarter, indicating that financial data will be disclosed in periodic reports as per regulations [2] - The main source of revenue for the company is from pharmaceutical sales, with key products including injectable thymosin alpha 1, injectable paclitaxel (albumin-bound), injectable somatostatin, injectable bivalirudin, and injectable clindamycin hydrochloride [2]